ArriVent BioPharma, Inc. 10-Q filing
Filed 2026-05-11 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001104659-26-058650
- Form type
- 10-Q
- CIK
- 0001868279
- Primary document
- https://www.sec.gov/Archives/edgar/data/1868279/000110465926058650/avbp-20260331x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for ArriVent BioPharma, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-46.1M | - | - |
| Net Income | $-43.3M | - | - |
| Eps Basic | -0.96 | - | - |
| Eps Diluted | -0.96 | - | - |
| Cash And Equivalents | $62.1M | - | - |
| Total Assets | $349.3M | - | - |
| Total Liabilities | $25.3M | - | - |
| Shareholders Equity | $324.0M | - | - |
| Operating Cash Flow | $-41.9M | - | - |